Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
1. A method of inhibiting the progress of prostate cancer, reducing the rate of progress of prostate cancer, halting the rate of progress of prostate cancer, alleviating symptoms of prostate cancer, and/or ameliorating prostate cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of the following formula:
or a pharmaceutically acceptable salt or solvate thereof;
wherein:
—R 5X is -L 5X -Q;
-L 5X - is independently a covalent single bond or -L 5XA -;
-L 5XA - is independently linear or branched saturated C 1-6 alkylene, and is optionally substituted with one or more groups selected from —OH and —OR L5X , wherein each —R L5X is independently linear or branched saturated C 1-6 alkyl or saturated C 3-6 cycloalkyl;
-Q is a pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, or diazepanyl, wherein the point of attachment is via a ring carbon atom, an is substituted with “n” groups -J, and is substituted with “m” groups —R Q ;
“n” is 1, 2, or 3;
“m” is 0, 1, 2, or 3;
each -J is independently —OH, —OR J , -L J -OH, or -L J -OR J ;
each —R J is independently linear or branched saturated C 1-6 alkyl or saturated C 3-6 cycloalkyl;
each -L J - is independently linear or branched saturated C 1-6 alkylene;
each —R Q is independently —F, —Cl, —Br, —I, —R QA , —CF 3 , —OCF 3 , —NH 2 , —NHR QA , —NR QA 2 , pyrrolidino, piperidino, morpholino, piperazino, N—(R QA )-piperazino, —SH, —SR QA , or —CN;
each —R QA is independently linear or branched saturated C 1-6 alkyl or saturated C 3-6 cycloalkyl;
—R 5Y is independently —H or —R 5YA ;
—R 5YA is independently linear or branched saturated C 1-6 alkyl;
—R 7 is independently —R 7X or —C(═O)R 7X ;
each —R 7X is independently:
—R 7A , —R 7B , —R 7C , —R 7D , —R 7E ,
-L 7 -R 7B , -L 7 -R 7C , -L 7 -R 7D , or -L 7 -R 7E ;
each -L 7 - is independently linear or branched saturated C 1-6 alkylene;
each —R 7A is independently linear or branched saturated C 1-6 alkyl, and is optionally substituted with one or more substituents —W 1 ;
each —R 7B is saturated C 3-6 cycloalkyl, and is optionally substituted with one or more substituents —W 2 ;
each —R 7C is non-aromatic C 3-7 heterocyclyl, and is optionally substituted with one or more substituents —W 2 ;
each —R 7D is phenyl or naphthyl, and is optionally substituted with one or more substituents —W 3 ;
each —R 7E is C 5-12 heteroaryl, and is optionally substituted with one or more substituents —W 3 ;
each —W 1 is independently:
—F, —Cl, —Br, —I, —CF 3 , —OH, —OR W1 , —OCF 3 , —NH 2 , —NHR W1 , —NR W1 2 , pyrrolidino, piperidino, morpholino, piperazino, N—(R W1 )-piperazino, —C(═O)OH, —C(═O)OR W1 , —C(═O)NH 2 , —C(═O)NHR W1 , —C(═O)NR W1 2 , —C(═O)-pyrrolidino, —C(═O)-piperidino, —C(═O)-morpholino, —C(═O)-piperazino, —C(═O)—N—(R W1 )-piperazino, —S(═O)R W1 ,—S(═O) 2 R W1 , —S(═O) 2 NH 2 , —S(═O) 2 NHR W1 , —S(═O) 2 NR W1 2 , —S(═O) 2 pyrrolidino, —S(═O) 2 -piperidino, —S(═O) 2 -morpholino, —S(═O) 2 -piperazino, —S(═O) 2 —N—(R W1 )-piperazino, —CN, or —NO 2 ;
wherein each —R W1 is independently linear or branched saturated C 1-6 alkyl, phenyl, or —CH 2 -phenyl, wherein each phenyl is optionally substituted with one or more groups selected from —F, —Cl, —Br, —I, —R W11 , —CF 3 , —OH, —OR W11 , and —OCF 3 , wherein each —R W11 is independently linear or branched saturated C 1-6 alkyl;
each —W 2 is independently:
—F, —Cl, —Br, —I, —R W2 , —CF 3 , —OH, —OR W2 , —OCF 3 , —NH 2 , —NHR W2 , —NR W2 2 , pyrrolidino, piperidino, morpholino, piperazino, N—(R W2 )-piperazino, —C(═O)OH, —C(═O)OR W2 , —C(═O)NH 2 , —C(═O)NHR W2 , —C(═O)NR W2 2 , —C(═O)-pyrrolidino, —C(═O)-piperidino, —C(═O)-morpholino, —C(═O)-piperazino, —C(═O)—N—(R W2 )-piperazino, —S(═O)R W2 , —S(═O) 2 R W2 , —S(═O) 2 NH 2 , —S(═O) 2 NHR 2 , —S(═O) 2 NR W2 2 , —S(═O) 2 pyrrolidino, —S(═O) 2 -piperidino, —S(═O) 2 -morpholino, —S(═O) 2 -piperazino, —S(═O) 2 —N—(R W2 )-piperazino, —CN, or —NO 2 ;
wherein each —R W2 is independently linear or branched saturated C 1-6 alkyl, phenyl, or —CH 2 -phenyl, wherein each phenyl is optionally substituted with one or more groups selected from —F, —Cl, —Br, —I, —R W22 , —CF 3 , —OH, —OR W22 , and —OCF 3 , wherein each —R W22 is independently linear or branched saturated C 1-6 alkyl;
each —W 3 is independently:
—F, —Cl, —Br, —I, —R W3 , —CF 3 , —OH, —OR W3 , —OCF 3 , —NH 2 , —NHR W3 , —NR W3 2 , pyrrolidino, piperidino, morpholino, piperazino, N—(R W3 )-piperazino, —C(═O)OH, —C(═O)OR W3 , —C(═O)NH 2 , —C(═O)NHR W3 , —C(═O)NR W3 2 , —C(═O)-pyrrolidino, —C(═O)-piperidino, —C(═O)-morpholino, —C(═O)-piperazino, —C(═O)—N—(R W3 )-piperazino, —S(═O)R W3 , —S(═O) 2 R W3 , —S(═O) 2 NH 2 , —S(═O) 2 NHR W3 , —S(═O) 2 NR W3 2 , —S(═O) 2 pyrrolidino, —S(═O) 2 -piperidino, —S(═O) 2 -morpholino, —S(═O) 2 -piperazino, —S(═O) 2 —N—(R W3 )-piperazino, —CN, or —NO 2 ;
wherein each —R W3 is independently linear or branched saturated C 1-6 alkyl, phenyl, or —CH 2 -phenyl, wherein each phenyl is optionally substituted with one or more groups selected from —F, —Cl, —Br, —I, —R W33 , —CF 3 , —OH, —OR W33 , and —OCF 3 , wherein each —R W33 is independently linear or branched saturated C 1-6 alkyl;
—R 3 is independently —R 3A or —R 3B ;
—R 3A is independently linear or branched saturated C 1-6 alkyl;
—R 3B is saturated C 3-7 cycloalkyl;
—R 2 is independently —H or —R 2A ;
R 2A is independently —F, —Cl, —Br, —I, —R 2AA , —CF 3 , —OH, —OR 2AA , —OCF 3 , —NH 2 , —NHR 2AA , —NR 2AA 2 , pyrrolidino, piperidino, morpholino, piperazino, N—(R 2AA )-piperazino, —SH, —SR 2AA , or —CN;
each —R 2AA is independently linear or branched saturated C 1-6 alkyl;
—R 6 is independently —H or —R 6A ;
—R 6A is independently —F, —Cl, —Br, —I, —R 6AA , —CF 3 , —OH, —OR 6AA , —OCF 3 , —NH 2 , —NHR 6AA , —NR 6AA 2 , pyrrolidino, piperidino, morpholino, piperazino, N—(R 6AA )-piperazino, —SH, —SR 6AA , or —CN; and
each —R 6AA is independently linear or branched saturated C 1-6 alkyl.
2. A method according to claim 1 , wherein:
—R 5Y is —H;
—R 2 is —H; and
—R 6 is —H.
3. A method according to claim 2 , wherein:
-L 5x - is independently a covalent single bond or -L 5xA -; and
-L 5xA - is —CH 2 -.
4. A method according to claim 3 , wherein:
-Q is pyrrolidinyl, wherein the point of attachment is via a ring carbon atom, and is substituted with “n” groups -J, and is substituted with “m” groups —R Q ; or
-Q is piperidinyl, wherein the point of attachment is via a ring carbon atom, and is substituted with “n” groups -J, and is substituted with “m” groups —R Q .
5. A method according to claim 3 , wherein -Q is selected from:
6. A method according to claim 3 , wherein -Q is:
7. A method according claim 4 , wherein each -J is —OH.
8. A method according claim 5 , wherein each -J is —OH.
9. A method according claim 6 , wherein each -J is —OH.
10. A method according to claim 7 , wherein —R 3 is —R 3A ; and —R 3A is -iPr.
11. A method according to claim 8 , wherein —R 3 is —R 3A ; and —R 3A is -iPr.
12. A method according to claim 9 , wherein —R 3 is —R 3A ; and —R 3A is -iPr.
13. A method according to claim 4 , wherein —R 7 is —R 7x ; and —R 7x is independently: —R 7C , —R 7D , —R 7E , -L 7 -R 7B , -L 7 -R 7D , or -L 7 -R 7E .
14. A method according to claim 7 , wherein —R 7 is —R 7x ; and —R 7x is independently: —R 7C , —R 7D , —R 7E , -L 7 -R 7B , -L 7 -R 7D , or -L 7 -R 7E .
15. A method according to claim 10 , wherein —R 7 is —R 7x ; and —R 7x is independently: —R 7C , —R 7D , —R 7E , -L 7 -R 7B , -L 7 -R 7D , or -L 7 -R 7E .
16. A method according to claim 12 , wherein —R 7 is —R 7x ; and —R 7x is independently: —R 7C , —R 7D , —R 7E , -L 7 -R 7B , -L 7 -R 7D , or -L 7 -R 7E .
17. A method according to claim 4 , wherein:
—R 7 is —R 7x ;
—R 7X is independently: —R 7C , —R 7D , —R 7E , -L 7 -R 7B , -L 7 -R 7D , or -L 7 -R 7E ;
each -L 7 - is —CH 2 —;
each —R 7B is cyclohexyl, and is optionally substituted with one or more substituents —W 2 ;
each —R 7C is independently piperidinyl, and is optionally substituted with one or more substituents —W 2 ;
each —R 7D is phenyl, and is optionally substituted with one or more substituents —W 3 ; and
each —R 7E is pyridyl, and is optionally substituted with one or more substituents —W 3 ;
wherein:
each —W 2 is independently: —F, —Cl, —Br, —I, —CF 3 , —OH, —OR w2 , —OCF 3 , or —CN;
each —R w2 is independently linear or branched saturated C 1 - 4 alkyl;
each —W 3 is independently: —F, —Cl, —Br, —I, —CF 3 , —OH, —OR w3 , —OCF 3 , or —CN; and
each —R w3 is independently linear or branched saturated C 1 - 4 alkyl.
18. A method according to claim 4 , wherein:
—R 7 is —R 7x ;
—R 7x is -L 7 -R 7D ;
-L 7 - is —CH 2 —;
—R 7D is phenyl, and is optionally substituted with one or more substituents —W 3 ;
each —W 3 is independently: —F, —Cl, —Br, —I, —CF 3 , —OH, —OR w3 , —OCF 3 , or —CN; and
each —R w3 is independently linear or branched saturated C 1 - 4 alkyl.
19. A method according to claim 6 , wherein:
—R 7 is —R 7x ;
—R 7x is -L 7 -R 7D ;
-L 7 - is —CH 2 —;
—R 7D is phenyl, and is optionally substituted with one or more substituents —W 3 ;
each —W 3 is independently: —F, —Cl, —Br, —I, —CF 3 , —OH, —OR w3 , —OCF 3 , or —CN; and
each —R w3 is independently linear or branched saturated C 1 - 4 alkyl.
20. A method according to claim 7 , wherein:
—R 7 is —R 7x ;
—R 7x is -L 7 -R 7D ;
-L 7 - is —CH 2 —;
—R 7D is phenyl, and is optionally substituted with one or more substituents —W 3 ;
each —W 3 is independently: —F, —Cl, —Br, —I, —CF 3 , —OH, —OR w3 , —OCF 3 , or —CN; and
each —R w3 is independently linear or branched saturated C 1 - 4 alkyl.
21. A method according to claim 9 , wherein:
—R 7 is —R 7x ;
—R 7x is -L 7 -R 7D ;
-L 7 - is —CH 2 —;
—R 7D is phenyl, and is optionally substituted with one or more substituents —W 3 ;
each —W 3 is independently: —F, —Cl, —Br, —I, —CF 3 , —OH, —OR w3 , —OCF 3 , or —CN; and
each —R w3 is independently linear or branched saturated C 1 - 4 alkyl.
22. A method according to claim 10 , wherein:
—R 7 is —R 7x ;
—R 7x is -L 7 -R 7D ;
-L 7 - is —CH 2 —;
—R 7D is phenyl, and is optionally substituted with one or more substituents —W 3 ;
each —W 3 is independently: —F, —Cl, —Br, —I, —CF 3 , —OH, —OR w3 , —OCF 3 , or —CN; and
each —R w3 is independently linear or branched saturated C 1 - 4 alkyl.
23. A method according to claim 12 , wherein:
—R 7 is —R 7x ;
—R 7x is -L 7 -R 7D ;
-L 7 - is —CH 2 —;
—R 7D is phenyl, and is optionally substituted with one or more substituents —W 3 ;
each —W 3 is independently: —F, —Cl, —Br, —I, —CF 3 , —OH, —OR w3 , —OCF 3 , or —CN; and
each —R w3 is independently linear or branched saturated C 1 - 4 alkyl.
24. A method according to claim 23 , wherein -L 5x - is -L 5xA -.
25. A method of inhibiting the progress of prostate cancer, reducing the rate of progress of prostate cancer, halting the rate of progress of prostate cancer, alleviating symptoms of prostate cancer, and/or ameliorating prostate cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound selected from compounds of the following formulas and pharmaceutically acceptable salts thereof:
26. A method of inhibiting the progress of prostate cancer, reducing the rate of progress of prostate cancer, halting the rate of progress of prostate cancer, alleviating symptoms of prostate cancer, and/or ameliorating prostate cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound selected from a compound of the following formula and pharmaceutically acceptable salts thereof: